A Look Inside HIV Resistance through Retroviral Protease Interaction Maps

Retroviruses affect a large number of species, from fish and birds to mammals and humans, with global socioeconomic negative impacts. Here the authors report and experimentally validate a novel approach for the analysis of the molecular networks that are involved in the recognition of substrates by retroviral proteases. Using multivariate analysis of the sequence-based physiochemical descriptions of 61 retroviral proteases comprising wild-type proteases, natural mutants, and drug-resistant forms of proteases from nine different viral species in relation to their ability to cleave 299 substrates, the authors mapped the physicochemical properties and cross-dependencies of the amino acids of the proteases and their substrates, which revealed a complex molecular interaction network of substrate recognition and cleavage. The approach allowed a detailed analysis of the molecular–chemical mechanisms involved in substrate cleavage by retroviral proteases.

[1]  Peteris Prusis,et al.  Proteochemometrics: A Tool for Modeling the Molecular Interaction Space , 2005 .

[2]  J. Louis,et al.  Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. , 2000, European journal of biochemistry.

[3]  Irene T Weber,et al.  Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. , 2002, European journal of biochemistry.

[4]  Irene T. Weber,et al.  Studies on the Symmetry and Sequence Context Dependence of the HIV-1 Proteinase Specificity* , 1997, The Journal of Biological Chemistry.

[5]  J. Louis,et al.  Kinetic and modeling studies of S3-S3' subsites of HIV proteinases. , 1992, Biochemistry.

[6]  I. Weber,et al.  Comparative Studies on the Substrate Specificity of Avian Myeloblastosis Virus Proteinase and Lentiviral Proteinases (*) , 1996, The Journal of Biological Chemistry.

[7]  J. Leis,et al.  Altered Rous sarcoma virus Gag polyprotein processing and its effects on particle formation , 1997, Journal of virology.

[8]  A Wlodawer,et al.  Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates. , 1992, The Journal of biological chemistry.

[9]  J. Louis,et al.  Effect of serine and tyrosine phosphorylation on retroviral proteinase substrates. , 1999, European journal of biochemistry.

[10]  Arthur J. Olson,et al.  Alteration of Substrate and Inhibitor Specificity of Feline Immunodeficiency Virus Protease , 2000, Journal of Virology.

[11]  I. Wakeling,et al.  A test of significance for partial least squares regression , 1993 .

[12]  Zachary Q. Beck,et al.  Molecular Basis for the Relative Substrate Specificity of Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Proteases , 2001, Journal of Virology.

[13]  W. Farmerie,et al.  Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. , 1996, Virology.

[14]  B. Dunn,et al.  Aspartic Peptidase Inhibitors: Implications in Drug Development , 2003, Critical reviews in biochemistry and molecular biology.

[15]  M. Lindgren,et al.  Investigation of an allosteric site of HIV-1 proteinase involved in inhibition by Cu2+. , 1998, Advances in experimental medicine and biology.

[16]  E. Freire,et al.  Designing drugs against heterogeneous targets , 2002, Nature Biotechnology.

[17]  S. Wold Cross-Validatory Estimation of the Number of Components in Factor and Principal Components Models , 1978 .

[18]  J. Randolph,et al.  Peptidomimetic inhibitors of HIV protease. , 2004, Current topics in medicinal chemistry.

[19]  L. Polgár,et al.  Rate-determining Steps in HIV-1 Protease Catalysis , 1996, The Journal of Biological Chemistry.

[20]  I. Weber,et al.  Mutational Analysis of the Substrate Binding Pocket of Murine Leukemia Virus Protease and Comparison with Human Immunodeficiency Virus Proteases (*) , 1995, The Journal of Biological Chemistry.

[21]  Peteris Prusis,et al.  Prediction of indirect interactions in proteins , 2006, BMC Bioinformatics.

[22]  A. Tomasselli,et al.  Actin, troponin C, Alzheimer amyloid precursor protein and pro-interleukin 1 beta as substrates of the protease from human immunodeficiency virus. , 1991, The Journal of biological chemistry.

[23]  I T Weber,et al.  Kinetic and modeling studies of subsites S4-S3' of Moloney murine leukemia virus protease. , 1994, The Journal of biological chemistry.

[24]  I. Weber,et al.  Studies on the substrate specificity of the proteinase of equine infectious anemia virus using oligopeptide substrates. , 1993, Biochemistry.

[25]  D B Evans,et al.  Human immunodeficiency virus type‐1 reverse transcriptase and ribonuclease h as substrates of the viral protease , 1993, Protein science : a publication of the Protein Society.

[26]  William G. Bardsley,et al.  Optimal design for model discrimination using the F-test with non-linear biochemical models. Criteria for choosing the number and spacing of experimental points , 1989 .

[27]  Marianne Manchester,et al.  Complete mutagenesis of the HIV-1 protease , 1989, Nature.

[28]  A Wlodawer,et al.  Comparison of the substrate-binding pockets of the Rous sarcoma virus and human immunodeficiency virus type 1 proteases. , 1993, The Journal of biological chemistry.

[29]  E. Freire,et al.  Adaptive inhibitors of the HIV-1 protease. , 2005, Progress in biophysics and molecular biology.

[30]  J. Louis,et al.  Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases. , 2000, European journal of biochemistry.

[31]  Alexander Wlodawer,et al.  Retroviral proteases , 2002, Genome Biology.

[32]  Sami Mahrus,et al.  Altered Substrate Specificity of Drug-Resistant Human Immunodeficiency Virus Type 1 Protease , 2002, Journal of Virology.

[33]  J. Louis,et al.  Cloning of the bovine leukemia virus proteinase in Escherichia coli and comparison of its specificity to that of human T-cell leukemia virus proteinase. , 2000, Biochimica et biophysica acta.

[34]  K. Chou,et al.  Studies on the specificity of HIV protease: An application of Markov chain theory , 1993, Journal of protein chemistry.

[35]  A Wlodawer,et al.  Programming the Rous Sarcoma Virus Protease to Cleave New Substrate Sequences (*) , 1996, The Journal of Biological Chemistry.

[36]  E. De Clercq,et al.  Strategies in the design of antiviral drugs , 2002, Nature reviews. Drug discovery.

[37]  A Wlodawer,et al.  Human Immunodeficiency Virus, Type 1 Protease Substrate Specificity Is Limited by Interactions between Substrate Amino Acids Bound in Adjacent Enzyme Subsites (*) , 1996, The Journal of Biological Chemistry.

[38]  J. Louis,et al.  Structural basis for specificity of retroviral proteases. , 1998, Biochemistry.

[39]  Thomas D. Wu,et al.  Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments , 2003, Journal of Virology.

[40]  Irene T Weber,et al.  Narrow Substrate Specificity and Sensitivity toward Ligand-binding Site Mutations of Human T-cell Leukemia Virus Type 1 Protease* , 2004, Journal of Biological Chemistry.

[41]  John M. Louis,et al.  Stabilization from Autoproteolysis and Kinetic Characterization of the Human T-cell Leukemia Virus Type 1 Proteinase* , 1999, The Journal of Biological Chemistry.

[42]  T. Lundstedt,et al.  Experimental design and optimization , 1998 .

[43]  C. Hutchison,et al.  Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. , 1991, The Journal of biological chemistry.

[44]  I. Weber,et al.  Comparison of inhibitor binding in HIV‐1 protease and in non‐viral aspartic proteases: the role of the flap , 1990, FEBS letters.

[45]  A Wlodawer,et al.  Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins. , 1992, The Journal of biological chemistry.

[46]  I. Weber,et al.  Studies on the role of the S4 substrate binding site of HIV proteinases , 1991, FEBS letters.

[47]  Arthur J. Olson,et al.  Structural Basis for Distinctions between Substrate and Inhibitor Specificities for Feline Immunodeficiency Virus and Human Immunodeficiency Virus Proteases , 2003, Journal of Virology.

[48]  S. Wold,et al.  New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acids. , 1998, Journal of medicinal chemistry.

[49]  Hugo Kubinyi,et al.  Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective , 2004 .

[50]  A Wlodawer,et al.  Structural and biochemical studies of retroviral proteases. , 2000, Biochimica et biophysica acta.

[51]  Amalio Telenti,et al.  Update of the Drug Resistance Mutations in HIV-1: 2005. , 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[52]  Garrett M Morris,et al.  Defining HIV-1 protease substrate selectivity. , 2002, Current drug targets. Infectious disorders.

[53]  D Norbeck,et al.  Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor , 1994, Journal of virology.

[54]  R. Shoeman,et al.  Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[55]  T. Lundstedt,et al.  Proteo-chemometrics analysis of MSH peptide binding to melanocortin receptors. , 2002, Protein engineering.

[56]  K C Chou,et al.  Artificial neural network model for predicting HIV protease cleavage sites in protein , 1998 .

[57]  B. Efron Better Bootstrap Confidence Intervals , 1987 .

[58]  J. Louis,et al.  Effect of substrate residues on the P2' preference of retroviral proteinases. , 1999, European journal of biochemistry.

[59]  Arthur J. Olson,et al.  Viral Evolution in Response to the Broad-Based Retroviral Protease Inhibitor TL-3 , 2001, Journal of Virology.

[60]  Matthew J. Gonzales,et al.  Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs , 2001, Nucleic Acids Res..

[61]  A Wlodawer,et al.  Mutations that alter the activity of the Rous sarcoma virus protease. , 1992, The Journal of biological chemistry.

[62]  Irene T Weber,et al.  Combining mutations in HIV‐1 protease to understand mechanisms of resistance , 2002, Proteins.

[63]  K. Chou,et al.  Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method , 1996, Proteins.

[64]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[65]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[66]  T. Copeland,et al.  Comparison of the HIV‐1 and HIV‐2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag‐Pol polyproteins , 1991, FEBS letters.

[67]  M. Navia,et al.  Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 , 1989, Nature.

[68]  A Wlodawer,et al.  Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate. , 1998, Biochemistry.